What’s New in the ADA Standards of Medical Care in Diabetes William H. Herman, MD, MPH Stefan S. Fajans/GlaxoSmithKline Professor of Diabetes Professor of Internal Medicine and Epidemiology University of Michigan Director, Michigan Center for Diabetes Translational Research Chair, American Diabetes Association Professional Practice Committee
64
Embed
What’s New in the ADA Standards of Medical Care in Diabetes...What’s New in the ADA Standards of Medical Care in Diabetes William H. Herman, MD, MPH Stefan S. Fajans/GlaxoSmithKline
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
What’s New in the ADA Standards of
Medical Care in Diabetes William H. Herman, MD, MPH
Stefan S. Fajans/GlaxoSmithKline Professor of Diabetes Professor of Internal Medicine and Epidemiology
University of Michigan Director, Michigan Center for Diabetes Translational Research
Chair, American Diabetes Association Professional Practice Committee
Speaker Financial Disclosure Information
Dr. Herman serves on Data Safety Monitoring Boards for
Merck and Lexicon
Outline • Obesity management in the treatment of
type 2 diabetes • The role of SGLT-2 inhibitors and GLP-1
receptor agonists in the treatment of type 2 diabetes
• Controversies in lipid management in diabetes
Outline • Obesity management in the treatment of
type 2 diabetes • The role of SGLT-2 inhibitors and GLP-1
receptor agonists in the treatment of type 2 diabetes
• Controversies in lipid management in diabetes
Medical Nutrition Therapy There is no one-size-fits-all eating pattern for individuals with diabetes.
ADA. Standards of Care, 2016
Goals of Medical Nutrition Therapy for Adults with Diabetes • To promote and support healthful eating
patterns, emphasizing a variety of foods in appropriate portion sizes, in order to improve overall health and to ‒ Attain individualized glycemic, blood
pressure, and lipid goals ‒ Delay or prevent complications of diabetes ‒ Achieve and maintain body weight goals
ADA. Standards of Care, 2016
Diet Recommendations • Diet, physical activity, and behavioral
therapy designed to achieve 5% weight loss should be prescribed for overweight and obese patients with type 2 diabetes ready to achieve weight loss.
• Interventions should be high intensity (≥16 sessions in 6 months) and offer long-term weight maintenance counseling.
ADA. Diabetes Care 39(Suppl 1):S47, 2016
Components and Costs of High Intensity Commercial or Proprietary Weight-Loss Programs
Program Nutrition Physical Activity
Behavioral Strategies Support
Monthly Cost, $
Weight Watchers
Low-calorie conventional foods
Activity tracking
Self-monitoring
Group sessions Online coaching Online community forum
43
Jenny Craig Low-calorie meal replacements
Encourages increased activity
Goal setting Self-monitoring
1-on-1 counseling 570
Nutrisystem Low-calorie meal replacements
Exercise plans Self-monitoring
1-on-1 counseling Online community forum
280
HMR Very-low-calorie or low-calorie meal replacements
Encourages increased activity
Goal setting Group sessions Telephone coaching Medical supervision
682
Medifast Very-low-calorie or low-calorie meal replacements
Encourages increased activity
Self-monitoring
1-on-1 counseling Online coaching
424
OPTIFAST Very-low-calorie or low-calorie meal replacements
Encourages increased activity
Problem solving
1-on-1 counseling Group support Medical supervision
665
Adapted from KA Gudzune. Ann Int Med 162:501, 2015
Differences in Mean Percentage of Weight Change with Low Calorie* and Very Low Calorie**
Weight-Loss Programs over Time
2.7 4.1
2.8 2.9
9.3 8.2
3.0
0
10
3 mos 6 mos 12 mos 24 mos
Difference in
Mean % Weight Change
LCDVLCD
Adapted from KA Gudzune. Ann Int Med 162:501, 2015
* Weight Watchers ** HMR or Optifast
Look AHEAD • RCT that examined whether weight loss in
overweight and obese individuals with type 2 diabetes reduces cardiovascular morbidity and mortality over 11 years (median 9.6 yrs)
• Randomized 5,145 overweight or obese individuals to: – Intensive lifestyle intervention – Diabetes support and education (control)
The Look AHEAD Research Group. NEJM 2013;369:145
Intensive Lifestyle Intervention participants had greater weight loss at every time point
Diabetes Support & Education
Intensive Lifestyle Intervention
-2.1%
-3.5%
-8.5%
-4.66% -4.7% -6.0%
The Look AHEAD Research Group. NEJM 2013;369:145
Intensive Lifestyle Intervention participants had greater improvements in HbA1c
The Look AHEAD Research Group. NEJM 2013;369:145
Diabetes Support & Education
Intensive Lifestyle Intervention
Intensive Lifestyle Intervention did not reduce cardiovascular morbidity and mortality
The Look AHEAD Research Group. NEJM 2013;369:145
But… the Intensive Lifestyle Intervention had other positive effects: • Partial remission of diabetes • Improvements in physical functioning,
mobility, and quality-of-life • Reductions in urinary incontinence, sleep
apnea, and depression
The Look AHEAD Research Group. NEJM 2013;369:145
Pharmacotherapy Recommendations • Weight loss medications may be effective as
adjuncts to diet, physical activity, and behavioral counseling for selected patients with type 2 diabetes and BMI ≥27 kg/m2.
• If a patient’s response to weight loss medications is <5% after 3 months or if there are safety or tolerability issues at any time, the medication should be discontinued and alternative medications or treatment approaches should be considered.
ADA. Diabetes Care 39(Suppl 1):S47, 2016
FDA-Approved Medications for the Long-Term Treatment of Obesity
$239 8.9 kg 45-70% Paresthesia, xerostomia, constipation, headache
Topiramate is tertogenic (cleft lip/ palate)
Naltrexone/ bupropion
(Contrave)
Maximum dose: 16 mg/180 mg b.i.d.
$251 2.0-4.1 kg 36-57% Nausea, constipation, headache
Depression, mania, contra-indicated in seizure disorders
Liraglutide (Saxenda)
Maintenance dose: 3 mg s.c. q.d.
$1,385 5.8-5.9 kg 51-73% Nausea, vomiting, diarrhea, constipation, headache
Pancreatitis, acute renal failure, contraindicated with MTC or MEN2
Adapted from ADA. Diabetes Care 39(Suppl 1):S47, 2016
Bariatric Surgery Recommendations • Metabolic surgery should be recommended to treat type 2
diabetes in surgical candidates with BMI ≥40 kg/m2 (BMI ≥37.5 kg/m2 in Asian Americans), regardless of the level of glycemic control or complexity of glucose-lowering regimens, and in patients with BMI 35.0-39.9 kg/m2 (32.5-37.4 kg/m2 in Asian Americans) when hyperglycemia is inadequately controlled despite lifestyle and optimal medical therapy.
• Metabolic surgery should be considered for patients with type 2 diabetes and BMI 30.0-34.9 kg/m2 (27.5-32.4 kg/m2 in Asian Americans) if hyperglycemia is inadequately controlled despite optimal treatment with oral and/or injectable medications (including insulin).
F Rubino. Diabetes Care 39:861, 2016
Bariatric Surgery Recommendations • Metabolic surgery should be performed in high-
volume centers with multidisciplinary teams that are experienced in the management of diabetes and gastrointestinal surgery.
• Long-term support and annual medical monitoring of micronutrient and nutritional status must be provided to patients after surgery.
F Rubino. Diabetes Care 39:861, 2016
Metabolic Surgery: Baseline Characteristics of the STAMPEDE
Summary In placebo controlled trials, empagliflozin is: • moderately effective (~0.6% HbA1c ↓) • associated with weight loss (~3 kg ↓) • not associated with hypoglycemia • associated with GU infections • expensive (AWP $470 / mo)
Red Book, 2016
The EMPA-REG Outcome Trial compared the impact of empagliflozin and placebo when added to standard care on cardiovascular death, nonfatal MI, and nonfatal stroke in patients with type 2 diabetes and established cardiovascular disease.
B Zinman. N Engl J Med 373:2117, 2015
Eligibility criteria for the EMPA-REG Outcome Trial
• Adults ≥18 years of age with type 2 diabetes and cardiovascular disease and BMI <45 kg/m2, eGFR ≥30 ml/min, and HbA1c 7.0-10.0%
B Zinman. N Engl J Med 373:2117, 2015
B Zinman. N Engl J Med 373:2117, 2015
Cumulative Incidence of Nonfatal MI, Nonfatal Stroke, or Cardiovascular Death by
Treatment Group, EMPA-REG
Baseline Characteristics of the EMPA-REG Study Population
Characteristic* Placebo (N=2333)
Pooled empagliflozin (N=4687)
Age – years ± SD 63 ± 9 63 ± 9
Sex (% male) 72 71
Race (% White) 72 73
Body mass index – kg/m2 30.7 ± 5.2 30.6 ± 5.3
>10 years since diagnosis of type 2 diabetes (%) 57 57
Insulin treated (%) 49 48
Glycated hemoglobin (%) 8.08 ± 0.84 8.07 ± 0.85
CV risk factor (%)
Coronary artery disease 76 76
History of myocardial infarction 46 47
Coronary artery bypass graft 24 25
Cardiac failure 11 10
History of stroke 24 23
Peripheral artery disease 21 21
B Zinman. N Engl J Med 373:2117, 2015
The LEADER Trial compared the impact of liraglutide and placebo when added to standard care on cardiovascular death, nonfatal MI, and nonfatal stroke in patient with type 2 diabetes at high cardiovascular risk.
SP Marso. N Engl J Med 2016. DOI: 10.1056/NEJMoa1603827
Eligibility criteria for LEADER
• Adults ≥50 years of age with type 2 diabetes and cardiovascular disease or ≥60 with ≥1 cardiovascular risk factor and HbA1c ≥7.0%
SP Marso. N Engl J Med 2016. DOI: 10.1056/NEJMoa1603827
SP Marso. N Engl J Med 2016. DOI: 10.1056/NEJMoa1603827
Cumulative incidence of nonfatal MI, nonfatal stroke, or cardiovascular death by
treatment group, LEADER
Baseline Characteristics of the LEADER Study Population
Characteristic* Placebo (N=4672)
Liraglutide (N=4668)
Age – years ± SD 64 ± 7 64 ± 7
Sex (% male) 64 65
Body mass index – kg/m2 32.5 ± 6.3 32.5 ± 6.3
Diabetes duration, years 13 ± 8 13 ± 8
Glycated hemoglobin (%) 8.7 ± 1.5 8.7 ± 1.6
CVD risk factors (%)
Prior myocardial infarction 30 31
Prior revascularization 39 39
>50% stenosis of coronary, carotid, or lower extremity arteries
26 25
Documented asymptomatic cardiac ischemia 26 27
Documented symptomatic CHD 9 9
Prior stroke or transient ischemic attack 17 16
SP Marso. N Engl J Med 2016. DOI: 10.1056/NEJMoa1603827
U.S. Population with diagnosed type 2 diabetes by age, 2010
0
5
10
20-44 45-64 65+
Mill
ions
with
dia
bete
s
Age in years
Total = 21 million
U.S. Population with diagnosed type 2 diabetes reporting any heart
SP Marso. N Engl J Med 2016. DOI: 10.1056/NEJMoa1603827
HbA1c -0.5% Weight -2.4 kg
Systolic BP -2 mmHg
LEADER: Differences in cardiovascular
risk factors at 2-years follow-up
SP Marso. N Engl J Med 2016. DOI: 10.1056/NEJMoa1603827
Unresolved questions • What explains the cardiovascular
and survival benefits seen with empagliflozin and liraglutide? – Is it due to the combination of small
beneficial changes in multiple known cardiovascular risk factors?
– Is it due to unmeasured “off-target” effects?
If the cardiovascular and survival benefits of newer therapies are due to the combination of small beneficial effects on known risk factors, what benefits could be achieved by intensifying risk factor control using other, less expensive, glucose, blood pressure, and lipid lowering agents?
Conclusions • Newer therapies are expensive
–Empagliflozin $4,884 / year –Liraglutide $9,972 / year
• The costs of diabetes treatments must be carefully weighed against their likely benefits
Conclusions • Empagliflozin or liraglutide in
combination with metformin are reasonable options for initial dual therapy for type 2 diabetes
• Empagliflozin or liraglutide may be preferred treatments for older adults with type 2 diabetes and high cardiovascular risk
Outline • Obesity management in the treatment of
type 2 diabetes • The role of SGLT-2 inhibitors and GLP-1
receptor agonists in the treatment of type 2 diabetes
• Controversies in lipid management in diabetes
Recommendation for Statin Treatment in People with Diabetes
Age Risk factors Recommended statin intensity <40 years None None
ASCVD risk factor(s)* Moderate or high ASCVD High
40-75 years None Moderate ASCVD risk factors High ASCVD High
>75 years None Moderate ASCVD risk factors Moderate or high ASCVD High
ADA. Diabetes Care 39(Suppl 1):S60, 2016
*ASCVD risk factors include LDL cholesterol ≥100 mg/dL (2.6 mmol/L), high blood pressure, smoking, overweight and obesity, and family history of premature ASCVD.
High-intensity and moderate-intensity statin therapy*
High-intensity statin therapy Moderate-intensity statin therapy Lowers LDL cholesterol by ≥50% Lowers LDL cholesterol by 30% to <50% Atorvastatin 40-80 mg Atorvastatin 10-20 mg Rosuvastatin 20-40 mg Rosuvastatin 5-10 mg
Where do non-statin lipid lowering therapies fit into the management of dyslipidemia
in diabetes?
IMPROVE-IT
CP Cannon. N Engl J Med 372:2387, 2015
Efficacy of Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
CP Cannon. N Engl J Med 372:2387, 2015
Lipid Management • The addition of exetimibe to moderate-
intensity statin therapy provides additional cardiovascular benefit compared with moderate-intensity statin therapy alone and may be considered for patients with a recent acute coronary syndrome with LDL cholesterol ≥50 mg/dL who cannot tolerate high-intensity statin therapy.
ADA. Diabetes Care 39(Suppl 1):S60, 2016
Lipid Management, continued • Combination therapy (statin/fibrate) has not
been shown to improve atherosclerotic cardiovascular disease outcomes and is generally not recommended. However, therapy with statin and fenofibrate may be considered for men and both triglyceride level ≥204 mg/dL and HDL cholesterol level ≤34 mg/dL.
ADA. Diabetes Care 39(Suppl 1):S60, 2016
Lipid Management, continued • Combination therapy (statin/niacin) has not
been shown to provide additional cardiovascular benefit above statin therapy alone and may increase the risk of stroke and is not generally recommended.
ADA. Diabetes Care 39(Suppl 1):S60, 2016
Does statin therapy increase the risk of type 2 diabetes?
Association Between Statin Therapy and Incident Diabetes in 13 Major Cardiovascular Trials
N Sattar. Lancet 375:735, 2010
Overall (P=11.2% [95% CI 0.0-50.2%]) 1.09 (1.02-1.17)
Association Between Different Statins and Development of Diabetes
N Sattar. Lancet 375:735, 2010
Atorvastatin
Simvastatin Rosuvastatin Pravastatin Lovastatin
Overall 1.09 (1.02-1.17)
1.14 (0.89-1.46)
1.11 (0.97-1.26)
1.18 (1.04-1.33)
1.03 (0.90-1.19)
0.98 (0.70-1.38)
How do the benefits of statin therapy compare to the risks of
statin therapy?
Treating 255 nondiabetic patients with statins for 4 years will result in: • 1 additional case of diabetes • 5.1 fewer cardiovascular events
N Sattar. Lancet 375:735, 2010
Do statins cause cognitive impairment?
Statins and Cognitive Function: A Systematic Review
Dementia
Alzheimer disease
Mild cognitive impairment
0.87 (0.82-0.92)
0.79 (0.63-0.99)
0.66 (0.51-0.86)
Favors Statin Users Favors Nonusers K R
icha
rdso
n. A
nn In
tern
Med
159
:688
, 201
3
Outline • Obesity management in the treatment of
type 2 diabetes • The role of SGLT-2 inhibitors and GLP-1
receptor agonists in the treatment of type 2 diabetes